Zoetis is a drug manufacturers - specialty & generic business based in the US. Zoetis shares (ZTS) are listed on the NYSE and all prices are listed in US Dollars. Zoetis employs 14,100 staff and has a trailing 12-month revenue of around $8.9 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $189.23 |
|---|---|
| 52-week range | $144.46 - $200.41 |
| 50-day moving average | $181.02 |
| 200-day moving average | $179.32 |
| Wall St. target price | $220.12 |
| PE ratio | 36.6015 |
| Dividend yield | $1.614 (0.93%) |
| Earnings per share (TTM) | $5.17 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $189.23 from 2024-09-06
| 1 week (2024-08-30) | 3.13% |
|---|---|
| 1 month (2024-08-08) | 0.49% |
| 3 months (2024-06-07) | 6.96% |
| 6 months (2024-03-08) | 3.88% |
| 1 year (2023-09-08) | 1.86% |
|---|---|
| 2 years (2022-09-08) | 19.40% |
| 3 years (2021-09-08) | 209.33 |
| 5 years (2019-09-06) | 49.69% |
Valuing Zoetis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zoetis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Zoetis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, Zoetis shares trade at around 37x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Zoetis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.6149. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zoetis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Zoetis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.6 billion.
The EBITDA is a measure of a Zoetis's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $8.9 billion |
|---|---|
| Operating margin TTM | 38.37% |
| Gross profit TTM | $5.6 billion |
| Return on assets TTM | 14.41% |
| Return on equity TTM | 48.89% |
| Profit margin | 26.29% |
| Book value | $10.94 |
| Market Capitalization | $85.7 billion |
TTM: trailing 12 months
Dividend payout ratio: 30.16% of net profits
Recently Zoetis has paid out, on average, around 30.16% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.93% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zoetis shareholders could enjoy a 0.93% return on their shares, in the form of dividend payments. In Zoetis's case, that would currently equate to about $1.614 per share.
While Zoetis's payout ratio might seem fairly standard, it's worth remembering that Zoetis may be investing much of the rest of its net profits in future growth.
Zoetis's most recent dividend payout was on 3 September 2024. The latest dividend was paid out to all shareholders who bought their shares by 17 July 2024 (the "ex-dividend date").
Over the last 12 months, Zoetis's shares have ranged in value from as little as $144.4564 up to $200.4135. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zoetis's is 0.883. This would suggest that Zoetis's shares are less volatile than average (for this exchange).
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.